

# Jean Baptiste Beauval

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3128983/publications.pdf>

Version: 2024-02-01

51  
papers

2,102  
citations

361413

20  
h-index

243625

44  
g-index

63  
all docs

63  
docs citations

63  
times ranked

2760  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 417-427.	27.0	684
2	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. <i>European Urology</i> , 2019, 75, 506-514.	1.9	188
3	Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors. <i>Annals of Surgical Oncology</i> , 2016, 23, 4277-4283.	1.5	121
4	Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?. <i>World Journal of Urology</i> , 2014, 32, 109-114.	2.2	87
5	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2020, 77, 733-741.	1.9	85
6	Pathologic Findings in Radical Prostatectomy Specimens From Patients Eligible for Active Surveillance With Highly Selective Criteria: A Multicenter Study. <i>Urology</i> , 2012, 80, 656-660.	1.0	60
7	Radical Prostatectomy for High-risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-up in National Multicenter Study in 813 Patients and Assessment of Easy-to-use Prognostic Substratification. <i>Urology</i> , 2011, 78, 607-613.	1.0	55
8	Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy outcomes: a multicentre study. <i>BJU International</i> , 2018, 121, 916-922.	2.5	47
9	A combination of enhanced recovery after surgery and prehabilitation pathways improves perioperative outcomes and costs for robotic radical prostatectomy. <i>Cancer</i> , 2020, 126, 4148-4155.	4.1	41
10	The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. <i>World Journal of Urology</i> , 2016, 34, 347-352.	2.2	40
11	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. <i>European Urology Oncology</i> , 2020, 3, 739-747.	5.4	31
12	Robotic-assisted kidney transplantation in obese recipients compared to non-obese recipients: the European experience. <i>World Journal of Urology</i> , 2021, 39, 1287-1298.	2.2	30
13	Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. <i>World Journal of Urology</i> , 2017, 35, 587-593.	2.2	29
14	Ductal adenocarcinoma of the prostate: Clinical and biological profiles. <i>Prostate</i> , 2017, 77, 1242-1250.	2.3	26
15	Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. <i>World Journal of Urology</i> , 2014, 32, 1331-1338.	2.2	23
16	Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer. <i>BMC Urology</i> , 2016, 16, 26.	1.4	23
17	Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study. <i>World Journal of Urology</i> , 2018, 36, 897-904.	2.2	23
18	Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery. <i>World Journal of Urology</i> , 2020, 38, 2493-2500.	2.2	20

#	ARTICLE	IF	CITATIONS
19	Management of non-metastatic castrate-resistant prostate cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 70, 223-231.	7.7	17
20	Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 4251.	3.7	17
21	The use of hemostatic agents does not prevent hemorrhagic complications of robotic partial nephrectomy. <i>World Journal of Urology</i> , 2015, 33, 1815-1820.	2.2	16
22	Laparoscopic nephrectomy for polycystic kidney: comparison of the transperitoneal and retroperitoneal approaches. <i>World Journal of Urology</i> , 2016, 34, 901-906.	2.2	16
23	Off-Clamp versus On-Clamp Robotic Partial Nephrectomy: A Multicenter Match-Paired Case-Control Study. <i>Urologia Internationalis</i> , 2017, 99, 272-276.	1.3	16
24	Patient selection for laparoscopic excision of adrenal metastases: A multicenter cohort study. <i>International Journal of Surgery</i> , 2015, 24, 75-80.	2.7	15
25	Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR. <i>Progres En Urologie</i> , 2018, 28, 146-155.	0.8	13
26	Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 144-149.	4.4	13
27	Total intracorporeal robotic renal auto-transplantation: A new minimally invasive approach to preserve the kidney after major ureteral injuries. <i>International Journal of Surgery Case Reports</i> , 2018, 49, 176-179.	0.6	12
28	Predictive model of 1-year postoperative renal function after living donor nephrectomy. <i>International Urology and Nephrology</i> , 2017, 49, 793-801.	1.4	11
29	External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer. <i>BJU International</i> , 2014, 114, E113-E119.	2.5	10
30	Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. <i>World Journal of Urology</i> , 2017, 35, 1191-1197.	2.2	10
31	Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance. <i>World Journal of Urology</i> , 2020, 38, 663-671.	2.2	10
32	CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA3-LBA3.	1.6	10
33	Endoscopic enucleation for prostate larger than 60 mL: comparison between holmium laser enucleation and plasmakinetic enucleation. <i>World Journal of Urology</i> , 2021, 39, 2011-2018.	2.2	9
34	External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. <i>Prostate</i> , 2017, 77, 928-933.	2.3	8
35	Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter study. <i>World Journal of Urology</i> , 2019, 37, 1491-1498.	2.2	7
36	Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies. <i>Urology</i> , 2020, 137, 126-132.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Deep Neural Networks Outperform the CAPRA Score in Predicting Biochemical Recurrence After Prostatectomy. <i>Frontiers in Oncology</i> , 2020, 10, 607923.	2.8	7
38	Evaluation of the impact of a clinical pathway on the progression of acute urinary retention. <i>Neurourology and Urodynamics</i> , 2019, 38, 387-392.	1.5	6
39	Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study. <i>World Journal of Urology</i> , 2020, 38, 1735-1740.	2.2	6
40	One-day Prehabilitation Program Before Robotic Radical Prostatectomy in Daily Practice: Routine Feasibility and Benefits for Patients and Hospitals. <i>European Urology Open Science</i> , 2020, 21, 14-16.	0.4	6
41	The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies. <i>World Journal of Urology</i> , 2021, 39, 3315-3321.	2.2	6
42	Laparoscopy for living donor left nephrectomy: Comparison of three-dimensional and two-dimensional vision. <i>Clinical Transplantation</i> , 2019, 33, e13745.	1.6	4
43	A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 577.e1-577.e7.	1.6	4
44	Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 386-392.	1.6	4
45	Who is dying after nephrectomy for cancer? Study of risk factors and causes of death after analyzing morbidity and mortality reviews (UroCCR-33 study). <i>Progres En Urologie</i> , 2019, 29, 282-287.	0.8	3
46	Migration in last decade to high-risk prostate cancer after radical prostatectomy. <i>Progres En Urologie</i> , 2019, 29, 29-35.	0.8	3
47	Confirmation by Early Oncologic Outcomes After Surgery of the Accuracy of Intermediate-risk Prostate Cancer Classification Based on Magnetic Resonance Imaging Staging and Targeted Biopsy. <i>European Urology Open Science</i> , 2020, 21, 5-8.	0.4	3
48	What risk of prostate cancer led urologist to recommend prostate biopsies?. <i>Progres En Urologie</i> , 2015, 25, 1125-1131.	0.8	2
49	Predicting biochemical recurrence after prostatectomy: Can machine learning beat CAPRA score? Results of a multicentric retrospective analysis on 4,700 patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 343-343.	1.6	1
50	How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?. <i>Progres En Urologie</i> , 2022, 32, 32/6S43-32/6S53.	0.8	1
51	Narrative review of PET/CT performances at biochemical recurrence in prostate cancer after radical prostatectomy and impact on patient disease management. <i>Progres En Urologie</i> , 2022, 32, 32/6S33-32/6S42.	0.8	0